Apart from the problem of possible intrinsic TRAIL resistance, initially sensitive cancer cells may develop an inducible resistance upon TRAIL treatment, as reported for several cell types such as those of breast, colon, liver, and ovarian cancer [72,73,74]. This evidence concerns the gene TNFSF10 and ovarian carcinoma.